Curcumin nanomicelle versus curcumin improves lipid profile, stress oxidative factors and inflammatory markers in patients undergoing coronary elective angioplasty; A Randomized Clinical Trial

Abstract

Background: Curcumin exhibited antioxidant and anti-inflammatory effects. The aim of this study, assess and compare curcumin and nano-curcumin effects on lipid profile, oxidative stress index and inflammatory factors of heart patients. Methods: This Randomized, Double-Blind, Placebo-Controlled Clinical Trial conducted on 90 patients undergoing coronary elective angioplasty. Patients were randomly divided into 3 groups. The first group received a 500 mg capsule of curcumin daily. The second group received an 80 mg capsule of nano-curcumin daily. The placebo group also received capsules similar to curcumin for 8 weeks. Lipid profile, stress oxidative factors and inflammatory markers measured in baseline and end of the investigation.Results: At the end of study, statistically significant changes was seen in the total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL) in the intervention groups to the control group (p<0.05). These changes in the nano-curcumin group were greater than the curcumin group.Curcumin and nano-curcumin supplementation also caused a statistically significant improvement in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) in comparison to the placebo (p<0.05).Conclusion: Complementary therapy of cardiovascular patients with curcumin and nano-curcumin supplements, could improve lipid profile, stress oxidative index and, inflammatory factors. The effects of curcumin on nano formula may be better for cardiac patients due to high bioavailability. However, further investigation is suggested in this regard.

Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19

“…Furthermore, nanoformulations of curcumin could also be engineered for longer-retention, sustained release, and penetration across the mucus barrier ( Sung et al, 2007 ). Clinical studies of liposomal curcumin, microparticle curcumin, and micelle curcumin by oral delivery have been found to be safe ( Yallapu et al, 2015 ) and shown to be effective in reducing markers of oxidative stress ( Helli et al, 2021 ). Animal studies have shown that inhalable curcumin effectively mitigates lethal bacterial pneumonia ( Zhang et al, 2019 ).…”

Effect of nano‐curcumin on various diseases: A comprehensive review of clinical trials

“…Studies have shown that administration of 80-120 mg/day of nano-curcumin can improve patients with type two diabetes, [90][91][92] heart disease, 93 NAFLD, 94 lipid profile, 90,[93][94][95] and hemodialysis. 95,96 Nano-curcumin can exert these protective effects through its antioxidant and anti-inflammatory properties.…”

“…This pathway has an important function in the inflammatory process of the formation, progression, and rupture of atherosclerotic plaque by inhibiting MMPs activity. [98][99][100][101] Other studies indicated that administering 80 mg/day of nano-curcumin could ease diabetic complications, such as neuropathy and nephropathy. Patients who consumed nano-curcumin had decreased HbA1C, fasting blood glucose, estimated average glucose, 90 neuropathy scores, reflex score, foot pain, numbness, weakness, pinprick, temperature, light touch, vibration, 87 hs-CRP, 92 malondialdehyde (MDA), 90,102 and serum lipid parameters include TG, VLDL, total cholesterol, and LDL.…”